Astellas Gene Therapies
Clinical trials sponsored by Astellas Gene Therapies, explained in plain language.
A subsidiary of Astellas Pharma focused on gene therapy development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Pompe disease study aims to clear path for gene therapy Results expected Jun 2027 (estimated)
-
Gene therapy trial for rare muscle disease halted after severe side effects
Disease control OngoingThis trial tested a gene therapy called AT132 for X-linked myotubular myopathy (XLMTM), a rare muscle disease present at birth that causes severe breathing problems. The therapy aimed to deliver a healthy copy of the MTM1 gene to improve muscle function. However, the study was st…
Phase 2/3 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Gene therapy trial hopes to treat rare muscle disease
Disease control OngoingThis early-stage study tests a gene therapy called AT845 for adults with late-onset Pompe disease, a condition that weakens muscles. The treatment aims to deliver a working copy of the GAA gene to muscle cells. Eleven participants who have been on standard enzyme replacement ther…
Phase 1/2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene therapy trial for rare heart condition halted before it began
Disease control CancelledThis study was designed to test a new gene therapy called ASP2016 for heart problems caused by Friedreich Ataxia, a rare genetic disease. The therapy aimed to deliver a healthy copy of the faulty gene to help the heart. However, the study was withdrawn before any participants wer…
Phase 1 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Pompe disease study aims to clear path for gene therapy
Knowledge-focused OngoingThis study looks at people with late-onset Pompe disease to measure antibodies against a virus used in gene therapy and against the standard enzyme replacement therapy. It also checks for biomarkers in blood and urine. About 119 teenagers and adults will give samples over 2 years…
Sponsor: Astellas Gene Therapies • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC